REGULATORY
New Chuikyo Rep Abe Credits Key Premium for Accelerating Drug Development
Yoshihiro Abe, a new healthcare provider representative of the Central Social Insurance Medical Council (Chuikyo), offered a view on August 27 that the provisional pricing premium for new drug development is speeding up the development of unapproved drugs with medical…
To read the full story
Related Article
- Chuikyo Grants Unprecedented 60% Premium to Ono’s Opdivo
August 28, 2014
REGULATORY
- MHLW Taps Kawabata to Lead Drug Discovery Support Office
April 15, 2026
- MHLW Reviewing EMIS Data on Petro-Product Supply to Medical Institutions
April 15, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- LDP, Ishin to Explore Role of Private Insurance in Reform Talks
April 14, 2026
- Middle East War Hitting API Air Freight, Trade Group Warns
April 13, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





